NMPA Flight Inspections: Preparing for China's Unannounced Audits Under Order 14

In China, post-market surveillance for medical devices is exceptionally rigorous, and the most challenging regulatory action that a manufacturer can face is an unannounced inspection, commonly referred to as a "flight inspection" (飞行检查).

The framework for these unannounced audits was established under the former CFDA (now the National Medical Products Administration, or NMPA) through the "Provisions for Unannounced Inspection of Drugs and Medical Devices" (Decree No. 14), which went into effect on September 1, 2015. Flight inspections target both domestic and foreign manufacturers, and their unannounced nature makes compliance readiness a continuous operational requirement.

This article provides a detailed breakdown of China’s Order 14, outlining the regulatory triggers, the authority granted to NMPA inspectors, and tactical strategies for global manufacturers to maintain an inspection-ready Quality Management System (QMS).

1. Defining the "Flight Inspection" Action

Under Article 2 of Decree No. 14, a flight inspection is defined as:

"An unannounced supervisory inspection conducted by the food and drug supervision and administration department targeting the research, production, operation, and use of drugs and medical devices without prior notification."

For foreign manufacturers, the NMPA (often represented by the Center for Food and Drug Inspection, or CFDI) routinely executes these inspections. The audits are conducted in accordance with China’s Medical Device Good Manufacturing Practice (GMP) standards. Because there is no advance warning, there is no time to "clean up" documentation or remediate operational gaps.

2. Regulatory Triggers for Flight Inspections

NMPA flight inspections are risk-based and triggered by specific events. Under Article 8 of Decree No. 14, the regulatory authority may launch an unannounced inspection under any of the following circumstances:

1. Complaints and Reports (投诉举报): A whistleblower, competitor, or customer submits a report indicating potential quality or safety risks.
2. Testing/Inspection Failure (检验发现): Routine sample testing or testing conducted during registration indicates quality or compliance issues.
3. Adverse Event Monitoring (不良反应/事件监测): Surveillance data indicates safety issues or unexpected clinical failures.
4. Authenticity Doubts (真实性有疑问): Registration submission materials contain data or statements that raise suspicions during desk reviews.
5. Severe GMP Deviations (涉嫌严重违反质量管理规范): Initial audits or historic reports suggest systemic failures in the manufacturer's QMS.
6. Poor Credit Record (企业有严重不守信记录): The enterprise has a history of non-compliance, regulatory penalties, or credit failures in official records.
7. Other Situations (其他情形): Any other risk-based scenarios deemed necessary by the regulatory authority.

3. The Unannounced Inspector Protocol

Order 14 establishes strict protocols to ensure the surprise element of flight inspections. Understanding these protocols helps manufacturers prepare for the operational reality of an audit.

• No Prior Contact (Article 12): Inspectors are strictly prohibited from informing the target facility of their travel itinerary, arrival time, or the specific scope of the audit. They specify a location to meet as a team and immediately head to the production site.
• Minimum Inspector Count (Article 10): The inspection team must consist of at least two qualified inspectors who have signed a conflict-of-interest declaration.
• On-Site Coordination (Article 13): Local provincial or municipal NMPA officials may be notified at the last minute to assist the national inspection team, ensuring local authority is present to enforce cooperation.

4. On-Site Investigative Powers (Articles 16–19)

Once inspectors arrive on-site, they possess broad investigative powers to secure evidence. Decree No. 14 distributes these powers across several articles: under Articles 16 and 17, the inspected organization must open relevant areas and provide true, complete documents, records, and electronic data, and the inspection team may collect or copy materials and take photographs and video of equipment, facilities, materials, and site conditions. Under Article 18, the team may draw product samples for testing by certified technical institutions (with testing fees borne by the organizing authority). Under Article 19, where evidence may be lost or difficult to acquire later, the team may trigger administrative compulsory measures through the local department. In practice this means:

• Access and Copy Documentation (Articles 16–17): Review and photocopy QMS files, production logs, batch records, and training records that the organization is obligated to provide.
• Media Recording (Article 17): Take photographs and capture video of production lines, warehouse storage, cleanrooms, and testing labs.
• Product Sampling (Article 18): Withdraw random product samples for laboratory analysis by certified institutions.
• Sealing and Evidence Preservation (Article 19): Place official seals on, or otherwise preserve, suspect materials, components, finished products, or production areas when evidence may otherwise be lost.

Manufacturers are legally obligated to cooperate under Article 5. Attempting to delay entry, hide documents, or refuse access is categorized as non-cooperation and can result in immediate suspension of the manufacturer's import license or product registration.

5. Tactical Playbook: Maintaining NMPA GMP Readiness

To manage the compliance risk of an unannounced NMPA flight inspection, global manufacturers should implement a permanent readiness protocol:

A. Establish a "Frontroom-Backroom" Reception Protocol

Create a defined procedure for the moment inspectors arrive at the facility gate:

• Ensure front-desk staff are trained to verify credentials and immediately contact the designated regulatory and quality representatives.
• Prepare a designated meeting room (Frontroom) for inspectors, while a coordination team (Backroom) retrieves requested documentation.

B. Ensure Language Compliance (Order 6 & NMPA Guidelines)

Under China’s Order 6 (说明书和标签管理规定), Chinese is the mandatory language for instructions and labels, and NMPA inspectors expect core QMS documentation to be accessible in Chinese or to have immediate translation capability. Keep key documents updated:

• Standard Operating Procedures (SOPs) for the Chinese market.
• Design History Files (DHF) and Device Master Records (DMR) for registered products.
• Complaint handling and adverse event reporting procedures.

C. Run Periodic Mock Flight Inspections

Do not wait for the NMPA to arrive to test your system:

• Task your internal audit team or an external consultant to conduct a mock "no-notice" audit of the facility.
• Evaluate how quickly the team can retrieve a complete batch record, calibration log, or raw material sterilization record.

Conclusion

NMPA flight inspections under Order 14 are an intensive regulatory action designed to enforce strict, ongoing compliance. By understanding the triggers, protocols, and inspector powers detailed in Decree No. 14, manufacturers can design an active readiness playbook that protects their Chinese market access and ensures patient safety.

Sources

• China Food and Drug Administration (CFDA) Decree No. 14: Provisions for Unannounced Inspection of Drugs and Medical Devices (effective September 1, 2015).
• National Medical Products Administration (NMPA) official website: Regulatory Measures for Medical Device Supervision and GMP Standards.
• China NMPA Order 6: Regulations on the Administration of Medical Device Instructions and Labels.